Consistent Effects of Canagliflozin (CANA) Across Racial Subgroups of Patients with Type 2 Diabetes Mellitus (T2DM)

被引：0
|
作者：
Gavin, James R., III
Davies, Melanie J.
Davies, Michael
Vija-Purkar, Ujjwala
Alba, Maria
机构：
来源：
DIABETES | 2014年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1095-P
引用
收藏
页码：A285 / A285
页数：1
相关论文
共 50 条
  • [41] Target Achievement and Quality Measure (QM) Attainment with Titrated Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM) as Add-on to Metformin (MET) plus Sitagliptin (SITA)
    Seufert, Jochen
    Aggarwal, Naresh
    Bailey, Robert
    Cao, Anjun
    Fung, Albert
    Pfeifer, Michael
    Alba, Maria
    Rodbard, Helena W.
    DIABETES, 2016, 65 : A308 - A308
  • [42] Effect of Canagliflozin (CANA) on Insulin Resistance (IR): Evaluation of Insulin Sensitivity (IS) by Using Euglycemic Hyperinsulinemic Clamp (EHC) Technique in Japanese Type 2 Diabetes Mellitus (T2DM) Patients
    Koike, Yoko
    Shirabe, Ichiro
    Maeda, Hajime
    Yoshimoto, Ayako
    Arai, Keiko
    Kumakura, Atsushi
    Hirao, Koichi
    Terauchi, Yasuo
    DIABETES, 2017, 66 : A332 - A332
  • [43] Time Until Insulin Initiation for Canagliflozin (CANA) vs. Sitagliptin (SITA) in Dual Therapy and Triple Therapy for Type 2 Diabetes Mellitus (T2DM) in the UK
    Schroeder, Melanie
    Chan, Edmond
    Willis, Michael
    Johansen, Pierre
    Nilsson, Andreas
    Schubert, Agata
    Neslusan, Cheryl
    DIABETES, 2016, 65 : A327 - A327
  • [44] Pathophysiology of type 2 diabetes (T2DM) in youth: Are there racial differences?
    Bacha, Fida
    Gungor, Neslihan
    Lee, Sojung
    Arslanian, Silva
    DIABETES, 2008, 57 : A506 - A506
  • [45] Assessment of Adverse Renal Effects in Patients with Type 2 Diabetes Mellitus (T2DM) Receiving Ertugliflozin
    Patel, Shrita M.
    Hickman, Mary A.
    Frederich, Robert
    Lauring, Brett
    Terra, Steven
    Johnson, Susan L.
    Huyck, Susan
    Mancuso, James P.
    DIABETES, 2018, 67
  • [46] Real-World Outcomes of Patients with Type 2 Diabetes Mellitus (T2DM) Treated with Canagliflozin in a US Managed Care Setting
    Chow, Wing
    Buysman, Erin K.
    Rupnow, Marcia F. T.
    Henk, Henry J.
    DIABETES, 2015, 64 : A347 - A348
  • [47] Regional effects of type 2 diabetes mellitus (T2DM) on grey matter atrophy
    Moran, C.
    Phan, T. G.
    Beare, R.
    Chen, J.
    Blizzard, L.
    Venn, A.
    Greenaway, T.
    Munch, G.
    Forbes, J.
    Pearson, S.
    Srikanth, V
    AUSTRALASIAN JOURNAL ON AGEING, 2012, 31 : 34 - 34
  • [48] Inappropriate metformin prescribing in elderly type 2 diabetes mellitus (T2DM) patients
    Kosmalski, M.
    Drozdowska, A.
    Sliwinska, A.
    Drzewoski, J.
    ADVANCES IN MEDICAL SCIENCES, 2012, 57 (01): : 65 - 70
  • [49] Cause of Hospitalizations in Patients with Type 2 Diabetes Mellitus (T2DM) in the CANVAS Program
    Mahaffey, Kenneth W.
    Ianus, Juliana
    Damaraju, C. V.
    Neal, Bruce
    De Zeeuw, Dick
    Fulcher, Greg
    Pfeifer, Michael
    Matthews, David R.
    DIABETES, 2019, 68
  • [50] ASSESSMENT OF THE KEY DRIVERS OF COST-EFFECTIVENESS IN THE ECONOMIC MODELLING OF CANAGLIFLOZIN (CANA) VERSUS GLIMEPIRIDE (GLIM) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN THE UK SETTING
    Thompson, G.
    Willis, M.
    Johansen, P.
    Neslusan, C.
    Schroeder, M.
    Girod, I
    VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
12345